Agios Pharmaceuticals | AGIO - Ebitda


Agios Pharmaceuticals reported $-108.66M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
AbbVie USD 3.69B 1.68B Mar/2026
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amgen USD 3.86B 1.28B Mar/2026
Arrowhead Research USD -107.35M 164.52M Mar/2026
Astellas Pharma JPY 235.24B 136.32B Jun/2026
AstraZeneca USD 5.16B 510M Jun/2026
Bayer EUR 2.14B 2.31B Jun/2026
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Eli Lilly USD 10.29B 1.86B Mar/2026
Exelixis USD 258.29M 15.43M Mar/2026
Gilead Sciences USD 3.51B 489M Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Moderna USD -1.26B 468M Mar/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Novartis USD 5.41B 431M Mar/2026
Pfizer USD 6.01B 18M Jun/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026